Add To Watchlist
Share URL
About The Company
Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases.
Read More
Overview
Value
0
Growth
20
Health
0
Management
0
Analyst Opinion
0
Total
20
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Does not hold enough liquid assets to cover short term liabilities
- Poor overall financial health
- Poor earnings and cashflow growth
Market Peers
UCBJY
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
N/A
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
N/A
Share Buybacks
N/A
Dividend Yeild (TTM)
N/A
Valuation
Value Score
0
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 23.9 USD ✘
Current Price: 44.5 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
N/A
PE/Earnings Growth
N/A
Price/Book
1.86x
Growth
Growth Score
20
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
N/A
Cashflow Growth
N/A
Health
Health Score
0
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.32x
Current Assets/Liabilities
0.64x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
1.42x
Management
Management Score
0
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
16.62%
Return On Assets
N/A
Return On Capital Employed
N/A
Return On Equity
N/A
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
0
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
UCB SA
Currency
USD
Beta
0.346274
Vol Avg
18778
Ceo
Mr. Jean-Christophe Tellier
Cik
Cusip
903480101
Exchange
Other OTC
Full Time Employees
8600
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2018-11-30
Address
Allée de la Recherche, 60
City
Brussels
State
Country
BE
Zip
1070
Phone
32 2 559 99 99
All financial data provided by FMP